NanoViricides, Inc. (NASDAQ:NNVC)

PRESS RELEASE

published on 05/14/2025 at 12:30, 1 year 1 month ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
NanoViricides, Inc. explains its drug strategy for combating viral infections and pandemics, focusing on development of antiviral nanomedicine drugs like NV-387

NanoViricides NV-387 Antiviral Nanomedicine Viral Infections
BRIEF

published on 05/08/2025 at 12:35, 1 year 1 month ago

Approval for NanoViricides' NV-387 Phase II Clinical Trial in DRC

NV-387 Clinical Trial Antiviral Drug Mpox Democratic Republic Of Congo
BRIEF

published on 05/08/2025 at 12:35, 1 year 1 month ago

Approbation de l'essai clinique de phase II du NV-387 de NanoViricides en RDC

NV-387 Essai Clinique Mpox Médicament Antiviral République Démocratique Du Congo
PRESS RELEASE

published on 05/08/2025 at 12:30, 1 year 1 month ago

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
NanoViricides, Inc. receives approval from CNES for Phase II clinical trial of NV-387 in DRC for MPox disease treatment. CEO highlights drug's broad-spectrum antiviral capabilities

NanoViricides, CNES Approval, Phase II Clinical Trial, NV-387, MPox Disease
BRIEF

published on 04/29/2025 at 12:35, 1 year 1 month ago

Potential Breakthrough in Measles Treatment: NanoViricides Develops Antiviral Drug

NanoViricides NV-387 Antiviral Drug Measles Treatment Endemic Disease
BRIEF

published on 04/29/2025 at 12:35, 1 year 1 month ago

Avancée potentielle dans le traitement de la rougeole : NanoViricides développe un médicament antiviral

NanoViricides NV-387 Médicament Antiviral Traitement De La Rougeole Maladie Endémique
PRESS RELEASE

published on 04/29/2025 at 12:30, 1 year 1 month ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
NanoViricides, Inc. provides details on its Measles drug development program targeting the endemic potential of the virus in the USA and the effectiveness of their broad-spectrum antiviral drug NV-387

NV-387 NanoViricides Inc. Broad-spectrum Antiviral Measles Drug Development Vaccination Decline
BRIEF

published on 04/14/2025 at 12:35, 1 year 2 months ago

Growing Measles Threat Spurs NanoViricides to Test Antiviral Solution

Measles Outbreak NanoViricides NV-387 Antiviral Solution Viral Spread FDA Emergency Access
BRIEF

published on 04/14/2025 at 12:35, 1 year 2 months ago

La menace croissante de la rougeole incite NanoViricides à tester une solution antivirale

Épidémie De Rougeole NanoViricides NV-387 Solution Antivirale Propagation Virale Accès D'urgence À La FDA
PRESS RELEASE

published on 04/14/2025 at 12:30, 1 year 2 months ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
NanoViricides, Inc. commences evaluation of clinical drug NV-387 for Measles virus treatment, utilizing innovative nanomedicine technology. Company aims to combat Measles outbreak and provide effective antiviral solution

NanoViricides NV-387 Antiviral Nanomedicine Measles

Published on 06/25/2026 at 15:30, 5 hours 48 minutes ago

Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation
Published on 06/25/2026 at 15:00, 6 hours 18 minutes ago

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
Published on 06/25/2026 at 14:30, 6 hours 48 minutes ago

Unusual Machines Expands Orlando Manufacturing Footprint to Support Battery Operations
Published on 06/25/2026 at 14:01, 7 hours 17 minutes ago

Worksport (NASDAQ:WKSP) Regains $1 Bid Price Requirement, Announces CEO Town Hall, Highlights Multiple Recent Growth Drivers in CEO Letter
Published on 06/25/2026 at 14:00, 7 hours 18 minutes ago

Horizon Aircraft's Leadership Team to Participate at Farnborough International Airshow 2026

View all ACCESSWIRE

Published on 06/25/2026 at 19:00, 2 hours 18 minutes ago

EQS-Adhoc: H&R GmbH & Co. KGaA resolves to prepare for the transition from the regulated market (Prime Standard) to the Scale segment of the Frankfurt Stock Exchange
Published on 06/25/2026 at 18:59, 2 hours 19 minutes ago

OHB Digital Connect completes upgrade of military ground stations
Published on 06/25/2026 at 18:40, 2 hours 38 minutes ago

Texas Cardiac Arrhythmia Institute at St. David's Medical Center hosts international conference on complex cardiac arrhythmias
Published on 06/25/2026 at 18:30, 2 hours 48 minutes ago

Delisting of Northern Data AG Shares - Munich Stock Exchange Decides on the Timeline
Published on 06/25/2026 at 18:00, 3 hours 18 minutes ago

EUROPLASMA: Projet de cession des activités de défense : poursuite des discussions

View all EQS

Published on 06/25/2026 at 18:45, 2 hours 33 minutes ago

Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 2 hours 48 minutes ago

Avis financier semestriel SIEHM au 30 avril 2026
Published on 06/25/2026 at 17:50, 3 hours 28 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 06/25/2026 at 17:50, 3 hours 28 minutes ago

DECLARATION D’ACTIONS ET DE DROITS DE VOTE
Published on 06/25/2026 at 15:58, 5 hours 20 minutes ago

260625 BENETEAU Transactions sur actions propres

View all LES ECHOS COMFI WIRE

News